Equities Analysts Issue Forecasts for AVTX Q3 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Avalo Therapeutics in a research note issued on Thursday, October 24th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.93) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($7.78) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2024 earnings at ($0.98) EPS, FY2024 earnings at ($35.47) EPS and FY2025 earnings at ($4.31) EPS.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing the consensus estimate of ($6.70) by ($7.37).

Avalo Therapeutics Stock Up 9.4 %

Shares of NASDAQ:AVTX opened at $14.44 on Monday. The business has a 50-day moving average of $9.47 and a two-hundred day moving average of $11.23. Avalo Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $34.46.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AVTX. Affinity Asset Advisors LLC increased its position in Avalo Therapeutics by 350.0% in the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after buying an additional 35,000 shares during the period. Logos Global Management LP bought a new position in Avalo Therapeutics during the second quarter worth $6,722,000. Finally, Ikarian Capital LLC acquired a new position in Avalo Therapeutics during the 1st quarter valued at $1,015,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.